Erasca, Inc.
ERASHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Erasca, Inc. (ERAS) is listed under Biotechnology. The company carries a $5.66B market cap, placing it firmly in the mid-cap category. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Market Cap
$5.66B
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
-25.98
EPS (TTM)
$-0.95
EPS (Fwd)
$-0.62
ROE
-78.3%
ROA
-21.4%
Cash
$268.7M
Total Debt
$44.7M
Free CF
-$210.5M
52W Change
905.6%
Annual Financials
Cash vs Debt
Where ERAS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ERAS finished 6.85% above its 150-day moving average ($15.32) and 28.80% above its 200-day moving average ($12.71). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ERAS overbought or oversold?
At the September 3, 2026 close, ERAS's RSI(14) was 40.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $268.7M in cash comfortably exceeding the $44.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$210.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -78.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Erasca, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Erasca, Inc. and its sector.